Amneal Pharmaceuticals (AMRX) Non Operating Income (2017 - 2026)

Amneal Pharmaceuticals' Non Operating Income history runs 10 years deep, the most recent figure standing at -$61.6 million for Q1 2026.

• On a quarterly basis, Non Operating Income rose 2.01% year-over-year to -$61.6 million in Q1 2026; TTM through Mar 2026 was -$253.6 million, a 16.14% increase from a year earlier, with the FY2025 full-year figure at -$254.9 million, up 16.25% from the prior year.
• Non Operating Income retreated to -$61.6 million in Q1 2026 per AMRX's latest filing, from -$56.8 million in the prior quarter.
• Across five years, Non Operating Income topped out at -$33.2 million in Q1 2022 and bottomed at -$93.6 million in Q4 2023.
• The 5-year median for Non Operating Income is -$59.7 million (2025), against an average of -$59.9 million.
• Across the five-year window, Non Operating Income sank 123.57% in 2023 and surged 37.66% in 2025, its largest moves.
• Year by year, Non Operating Income stood at -$41.8 million in 2022, then sank by 123.57% to -$93.6 million in 2023, then grew by 2.62% to -$91.1 million in 2024, then soared by 37.66% to -$56.8 million in 2025, then decreased by 8.45% to -$61.6 million in 2026.
• Per Business Quant, the three latest AMRX Non Operating Income figures stand at -$61.6 million (Q1 2026), -$56.8 million (Q4 2025), and -$75.6 million (Q3 2025).